PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

TTSE:6190
249.00
JPY
-1.00
(-0.40%)
3.67EPS
89.82P/E
1.34BMarket Cap
Feb 12Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
352.69
479.18
425.45
311.09
420.98
447.27
313.42
401.22
625.29
453.58
380.54
385.15
349.92
Basic EPS, GAAP
22.72
49.32
44.43
-93.36
-101.96
-141.84
-73.6
-117.5
145.23
6.98
-110.83
30.81
3.67
Free Cash Flow per Basic Share
-6.26
94.37
12.2
-66.73
-77.13
-14.75
-87.89
2.92
78.05
-31.22
-26
13.33
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
365.92
683.94
728.38
639.26
527.82
396
332.71
250.42
416.78
446.27
337.1
381.46
359.77
Tangible Book Value per Share
365.18
683.03
726.73
512.84
429.13
395.02
331.92
249.96
415.34
443.55
332.58
377.79
356.38
Basic Weighted Avg Shares
2
3
3
3
3
3
3
3
3
4
4
4
4
Sales/Revenue/Turnover
881
1,217
1,229
902
1,228
1,311
1,014
1,325
2,124
1,715
1,541
1,566
1,424
Operating Margin (%)
20.81
28.15
11.57
-29.77
-25.39
-11.19
-27.32
-12.65
23.94
0.65
-9.22
5.29
-2.41
Depreciation Expense
22
22
25
24
63
85
55
86
24
25
28
34
- -
Net Income, GAAP
57
125
128
-271
-297
-416
-238
-388
493
26
-449
125
15
Effective Tax Rate (%)
9.35
14.87
1.55
- -
- -
- -
- -
- -
3.39
55.88
- -
4.73
29.8
Profit Margin (%)
6.44
10.29
10.44
-30.01
-24.22
-31.71
-23.48
-29.28
23.23
1.54
-29.13
8
1.05
Working Capital
791
1,669
1,785
1,119
831
1,722
1,401
1,415
1,006
1,711
1,151
1,270
1,163
LT Debt
137
88
116
71
43
1,077
1,010
1,008
215
491
353
267
120
Total Equity
1,057
1,975
2,104
1,857
1,543
1,162
1,094
828
1,514
1,798
1,365
1,553
1,464
Return on Invested Capital (%)
- -
9.54
6.32
- -
- -
- -
- -
- -
21.42
0.19
- -
3.95
-1.37
Return on Capital (%)
- -
7.58
5.92
- -
- -
- -
- -
- -
22
1.07
- -
6.54
1.04
Return on Common Equity (%)
- -
8.26
6.29
-13.67
-17.5
-30.74
-21.1
-40.37
42.12
1.59
-28.39
8.58
1.05

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
180
220
180
LT Borrowings
160
140
120
LT Finance Leases
- -
127
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
1,970
1,791
1,343

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
1,639
1,643
1,528
Cash, Cash Equivalents & STI
1,054
1,148
1,104
Accounts Receivable, Net
197
136
76
Inventories
321
308
298
Total Current Liabilities
388
373
364
Payables & Accruals
- -
- -
- -
ST Debt
180
220
180
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.43%
13.39%
13.71%
Free Cash Flow
200.2%
448.75%
-151.47%
Net Income, GAAP
-249.03%
-437.72%
-127.89%
Sales/Revenue/Turnover
5.78%
12.65%
1.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
449
339
355
398
1,541
2026
400
356
444
365
1,566
2027
259
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.75
-36.63
-6.42
-73.61
-110.83
2026
4.74
-1.69
19.88
7.86
30.81
2027
-22.38
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Masakazu Kakuni
Full Time Employees
55
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
3-4-1 Kagamiyama Higashi-Hiroshima HI Japan 739-0046
IPO Date
Mar 18, 2016
Business
PhoenixBio Co., Ltd. (6190.T) develops and provides specialized contract research services for drug discovery and development, primarily utilizing its proprietary PXB-mouse, a chimeric mouse model with a highly humanized liver containing up to 90% human hepatocytes. The company offers PXB-mouse services for in vivo studies including drug metabolism and pharmacokinetics (DMPK), toxicology, viral hepatitis (HBV and HBV/HDV), nonalcoholic steatohepatitis (NASH/MASH)/NAFLD, gene-based therapeutics, oligonucleotide therapies, and custom transplantations; PXB-cells, fresh or cryopreserved human hepatocytes derived from PXB-mice for in vitro studies; and Tg & KO animal services with custom transgenic animals. It operates production and research facilities in Japan, the United States, and internationally, producing over 4,000 PXB-mice annually with consistent quality for global pharmaceutical and academic clients. Founded in 2002 and headquartered in Higashi-Hiroshima City, Japan, PhoenixBio maintains subsidiaries including PhoenixBio USA Corporation in New York and CMHL Consortium LLC in Delaware, USA, supporting project management, sales, and collaborative research consortia with pharmaceutical leaders. In February 2025, PhoenixBio entered a business partnership with TOPPAN Holdings Inc. to co-develop and commercialize artificial 3D liver tissue models combining TOPPAN's invivoid 3D cell culture technology with PhoenixBio's PXB-cells, enhancing applications in drug discovery, personalized cancer treatment, high-sensitivity liver toxicity evaluation, and translational research. The company continues active global engagement, with recent announcements for presentations on PXB-mouse and PXB-Shizuku technologies at conferences including CTRMS 2025, European Society of Gene and Cell Therapy, and ISSX 2025 in September 2025.